Dihydroartemisinin (DHA) induces ferroptosis and causes cell cycle arrest in head and neck carcinoma cells

Cancer Letters

Volumn 381, Issue 1, 2016, Pages 165-175

  Lin, Renyu ^a,b   Zhang, Ziheng ^a,b   Chen, Lingfeng ^c   Zhou, Yunfang ^d   Zou, Peng ^a,c   Feng, Chen ^a   Wang, Li ^a   Liang, Guang ^a,c  

^a WENZHOU MEDICAL UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

^c NANJING UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^d LISHUI PEOPLE S HOSPITAL   (China)

Author keywords

Antitumor; Cell cycle; Dihydroartemisinin; Ferroptosis; Head and neck cancer

Indexed keywords

CELL PROTEIN; DIHYDROARTEMISININ; FORKHEAD BOX PROTEIN M1; UNCLASSIFIED DRUG; ANGIOGENESIS INHIBITOR; ANGIOGENIC PROTEIN; ARTEMISININ DERIVATIVE; FOXM1 PROTEIN, HUMAN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CARCINOMA CELL LINE; CELL ACTIVITY; CELL CYCLE ARREST; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFECT; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; PHENOTYPE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; ANGIOGENESIS; CELL CYCLE CHECKPOINT; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECTS; GENETIC TRANSFECTION; GENETICS; HEAD AND NECK NEOPLASMS; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; RNA INTERFERENCE; TIME FACTOR; TUMOR CELL LINE; UMBILICAL VEIN ENDOTHELIAL CELL;

ANGIOGENESIS INHIBITORS; ANGIOGENIC PROTEINS; APOPTOSIS; ARTEMISININS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FORKHEAD BOX PROTEIN M1; HEAD AND NECK NEOPLASMS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSFECTION;

EID: 84981203604     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2016.07.033     Document Type: Article

References (50)

1. [1] Parkin, D.M., Bray, F., Ferlay, J., Pisani, P., Global cancer statistics, 2002. CA Cancer J. Clin 55 (2005), 74–108.
2. [2] Mao, L., Hong, W.K., Papadimitrakopoulou, V.A., Focus on head and neck cancer. Cancer Cell 5 (2004), 311–316.
3. [3] Ferlay, J., Shin, H.R., Bray, F., Forman, D., Mathers, C., Parkin, D.M., Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 127 (2010), 2893–2917.
4. [4] Marur, S., Forastiere, A.A., Head and neck squamous cell carcinoma: update on epidemiology, diagnosis, and treatment. Mayo Clin. Proc 91 (2016), 386–396.
5. [5] Price, K.A., Cohen, E.E., Current treatment options for metastatic head and neck cancer. Curr. Treat. Options Oncol 13 (2012), 35–46.
6. [6] Flobinus, A., Taudon, N., Desbordes, M., Labrosse, B., Simon, F., Mazeron, M.C., et al. Stability and antiviral activity against human cytomegalovirus of artemisinin derivatives. J. Antimicrob. Chemother 69 (2014), 34–40.
7. [7] Wu, C., Liu, J., Pan, X., Xian, W., Li, B., Peng, W., et al. Design, synthesis and evaluation of the antibacterial enhancement activities of amino dihydroartemisinin derivatives. Molecules 18 (2013), 6866–6882.
8. [8] Gao, N., Budhraja, A., Cheng, S., Liu, E.H., Huang, C., Chen, J., et al. Interruption of the MEK/ERK signaling cascade promotes dihydroartemisinin-induced apoptosis in vitro and in vivo. Apoptosis 16 (2011), 511–523.
9. [9] Singh, N.P., Lai, H., Selective toxicity of dihydroartemisinin and holotransferrin toward human breast cancer cells. Life Sci 70 (2001), 49–56.
10. [10] Zhang, C.Z., Zhang, H., Yun, J., Chen, G.G., Lai, P.B., Dihydroartemisinin exhibits antitumor activity toward hepatocellular carcinoma in vitro and in vivo. Biochem. Pharmacol 83 (2012), 1278–1289.
11. [11] Jiao, Y., Ge, C.M., Meng, Q.H., Cao, J.P., Tong, J., Fan, S.J., Dihydroartemisinin is an inhibitor of ovarian cancer cell growth. Acta Pharmacol. Sin 28 (2007), 1045–1056.
12. [12] Dell'Eva, R., Pfeffer, U., Vene, R., Anfosso, L., Forlani, A., Albini, A., et al. Inhibition of angiogenesis in vivo and growth of Kaposi's sarcoma xenograft tumors by the anti-malarial artesunate. Biochem. Pharmacol 68 (2004), 2359–2366.
13. [13] Tang, C., Ao, P.Y., Zhao, Y.Q., Huang, S.Z., Jin, Y., Liu, J.J., et al. Effect and mechanism of dihydroartemisinin on proliferation, metastasis and apoptosis of human osteosarcoma cells. J. Biol. Regul. Homeost. Agents 29 (2015), 881–887.
14. [14] Liu, W., Wang, D.W., Yu, S.Y., Cao, Y., Yang, L., E, X.Q., et al. The effect of dihydroartemisinin on the proliferation, metastasis and apoptosis of human osteosarcoma cells and its mechanism. J. Biol. Regul. Homeost. Agents 29 (2015), 335–342.
15. [15] Zhao, L., Wen, Z.H., Jia, C.H., Li, M., Luo, S.Q., Bai, X.C., Metformin induces G1 cell cycle arrest and inhibits cell proliferation in nasopharyngeal carcinoma cells. Anat. Rec. (Hoboken) 294 (2011), 1337–1343.
16. [16] Tong, Y., Liu, Y., Zheng, H., Zheng, L., Liu, W., Wu, J., et al. Artemisinin and its derivatives can significantly inhibit lung tumorigenesis and tumor metastasis through Wnt/β-catenin signaling. Oncotarget, 2016, 10.18632/oncotarget.8920.
17. [17] Hui, H.Y., Wu, N., Wu, M., Liu, Y., Xiao, S.X., Zhang, M.F., Dihydroartemisinin suppresses growth of squamous cell carcinoma A431 cells by targeting the Wnt/beta-catenin pathway. Anticancer Drugs 27 (2016), 99–105.
18. [18] Efferth, T., Olbrich, A., Bauer, R., mRNA expression profiles for the response of human tumor cell lines to the antimalarial drugs artesunate, arteether, and artemether. Biochem. Pharmacol 64 (2002), 617–623.
19. [19] Zhou, H.J., Wang, W.Q., Wu, G.D., Lee, J., Li, A., Artesunate inhibits angiogenesis and downregulates vascular endothelial growth factor expression in chronic myeloid leukemia K562 cells. Vascul. Pharmacol 47 (2007), 131–138.
20. [20] Dong, F., Tian, H., Yan, S., Li, L., Dong, X., Wang, F., et al. Dihydroartemisinin inhibits endothelial cell proliferation through the suppression of the ERK signaling pathway. Int. J. Mol. Med 35 (2015), 1381–1387.
21. [21] Huang, Z., Huang, X., Jiang, D., Zhang, Y., Huang, B., Luo, G., Dihydroartemisinin inhibits cell proliferation by induced G1 arrest and apoptosis in human nasopharyngealcarcinoma cells. J. Cancer Res. Ther 12 (2016), 244–247.
22. [22] Jia, L., Song, Q., Zhou, C., Li, X., Pi, L., Ma, X., et al. Dihydroartemisinin as a putative STAT3 inhibitor, suppresses the growth of head and neck squamous cell carcinoma by targeting Jak2/STAT3 signaling. PLoS ONE, 11, 2016 e0147157.
23. [23] Ooko, E., Saeed, M.E., Kadioglu, O., Sarvi, S., Colak, M., Elmasaoudi, K., et al. Artemisinin derivatives induce iron-dependent cell death (ferroptosis) in tumor cells. Phytomedicine 22 (2015), 1045–1054.
24. [24] Ba, Q., Zhou, N., Duan, J., Chen, T., Hao, M., Yang, X., et al. Dihydroartemisinin exerts its anticancer activity through depleting cellular iron via transferrin receptor-1. PLoS ONE, 7, 2012 e42703.
25. [25] Manz, D.H., Blanchette, N.L., Paul, B.T., Torti, F.M., Torti, S.V., Iron and cancer: recent insights. Ann. N. Y. Acad. Sci 1368 (2016), 149–161.
26. [26] Wang, S.J., Sun, B., Cheng, Z.X., Zhou, H.X., Gao, Y., Kong, R., et al. Dihydroartemisinin inhibits angiogenesis in pancreatic cancer by targeting the NF-kappaB pathway. Cancer Chemother. Pharmacol 68 (2011), 1421–1430.
27. [27] Qin, G., Zhao, C., Zhang, L., Liu, H., Quan, Y., Chai, L., et al. Dihydroartemisinin induces apoptosis preferentially via a Bim-mediated intrinsic pathway in hepatocarcinoma cells. Apoptosis 20 (2015), 1072–1086.
28. [28] Eling, N., Reuter, L., Hazin, J., Hamacher-Brady, A., Brady, N.R., Identification of artesunate as a specific activator of ferroptosis in pancreatic cancer cells. Oncoscience 2 (2015), 517–532.
29. [29] Dixon, S.J., Lemberg, K.M., Lamprecht, M.R., Skouta, R., Zaitsev, E.M., Gleason, C.E., et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 149 (2012), 1060–1072.
30. [30] Cao, J.Y., Dixon, S.J., Mechanisms of ferroptosis. Cell. Mol. Life Sci 73 (2016), 2195–2209.
31. [31] Friedmann Angeli, J.P., Schneider, M., Proneth, B., Tyurina, Y.Y., Tyurin, V.A., Hammond, V.J., et al. Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice. Nat. Cell Biol 16 (2014), 1180–1191.
32. [32] Schott, C., Graab, U., Cuvelier, N., Hahn, H., Fulda, S., Oncogenic RAS mutants confer resistance of RMS13 rhabdomyosarcoma cells to oxidative stress-induced ferroptotic cell death. Front. Oncol, 5, 2015, 131.
33. [33] Yagoda, N., von Rechenberg, M., Zaganjor, E., Bauer, A.J., Yang, W.S., Fridman, D.J., et al. RAS-RAF-MEK-dependent oxidative cell death involving voltage-dependent anion channels. Nature 447 (2007), 864–868.
34. [34] Dolma, S., Lessnick, S.L., Hahn, W.C., Stockwell, B.R., Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells. Cancer Cell 3 (2003), 285–296.
35. [35] Cognetti, D.M., Weber, R.S., Lai, S.Y., Head and neck cancer: an evolving treatment paradigm. Cancer 113 (2008), 1911–1932.
36. [36] Lu, J.J., Chen, S.M., Zhang, X.W., Ding, J., Meng, L.H., The anti-cancer activity of dihydroartemisinin is associated with induction of iron-dependent endoplasmic reticulum stress in colorectal carcinoma HCT116 cells. Invest. New Drugs 29 (2011), 1276–1283.
37. [37] Handrick, R., Ontikatze, T., Bauer, K.D., Freier, F., Rubel, A., Durig, J., et al. Dihydroartemisinin induces apoptosis by a Bak-dependent intrinsic pathway. Mol. Cancer Ther 9 (2010), 2497–2510.
38. [38] Lu, J.J., Meng, L.H., Shankavaram, U.T., Zhu, C.H., Tong, L.J., Chen, G., et al. Dihydroartemisinin accelerates c-MYC oncoprotein degradation and induces apoptosis in c-MYC-overexpressing tumor cells. Biochem. Pharmacol 80 (2010), 22–30.
39. [39] Beekman, A.C., Wierenga, P.K., Woerdenbag, H.J., Van Uden, W., Pras, N., Konings, A.W., et al. Artemisinin-derived sesquiterpene lactones as potential antitumour compounds: cytotoxic action against bone marrow and tumour cells. Planta Med 64 (1998), 615–619.
40. [40] Steinbruck, L., Pereira, G., Efferth, T., Effects of artesunate on cytokinesis and G(2)/M cell cycle progression of tumour cells and budding yeast. Cancer Genomics Proteomics 7 (2010), 337–346.
41. [41] Hosoya, K., Murahari, S., Laio, A., London, C.A., Couto, C.G., Kisseberth, W.C., Biological activity of dihydroartemisinin in canine osteosarcoma cell lines. Am. J. Vet. Res 69 (2008), 519–526.
42. [42] Perou, C.M., Sorlie, T., Eisen, M.B., van de Rijn, M., Jeffrey, S.S., Rees, C.A., et al. Molecular portraits of human breast tumours. Nature 406 (2000), 747–752.
43. [43] Kim, I.M., Ackerson, T., Ramakrishna, S., Tretiakova, M., Wang, I.C., Kalin, T.V., et al. The Forkhead Box m1 transcription factor stimulates the proliferation of tumor cells during development of lung cancer. Cancer Res 66 (2006), 2153–2161.
44. [44] Kalin, T.V., Wang, I.C., Ackerson, T.J., Major, M.L., Detrisac, C.J., Kalinichenko, V.V., et al. Increased levels of the FoxM1 transcription factor accelerate development and progression of prostate carcinomas in both TRAMP and LADY transgenic mice. Cancer Res 66 (2006), 1712–1720.
45. [45] Yoshida, Y., Wang, I.C., Yoder, H.M., Davidson, N.O., Costa, R.H., The forkhead box M1 transcription factor contributes to the development and growth of mouse colorectal cancer. Gastroenterology 132 (2007), 1420–1431.
46. [46] Ye, H., Kelly, T.F., Samadani, U., Lim, L., Rubio, S., Overdier, D.G., et al. Hepatocyte nuclear factor 3/fork head homolog 11 is expressed in proliferating epithelial and mesenchymal cells of embryonic and adult tissues. Mol. Cell. Biol 17 (1997), 1626–1641.
47. [47] Korver, W., Schilham, M.W., Moerer, P., van den Hoff, M.J., Dam, K., Lamers, W.H., et al. Uncoupling of S phase and mitosis in cardiomyocytes and hepatocytes lacking the winged-helix transcription factor Trident. Curr. Biol 8 (1998), 1327–1330.
48. [48] Zhang, W., Liu, H.T., MAPK signal pathways in the regulation of cell proliferation in mammalian cells. Cell Res 12 (2002), 9–18.
49. [49] Srinivasan, R., Zabuawala, T., Huang, H., Zhang, J., Gulati, P., Fernandez, S., et al. Erk1 and Erk2 regulate endothelial cell proliferation and migration during mouse embryonic angiogenesis. PLoS ONE, 4, 2009 e8283.
50. [50] Smith, B.D., Smith, G.L., Carter, D., Sasaki, C.T., Haffty, B.G., Prognostic significance of vascular endothelial growth factor protein levels in oral and oropharyngeal squamous cell carcinoma. J. Clin. Oncol 18 (2000), 2046–2052.